Clinuvel says photoprotective drug positive in Phase III trial for rare light disease
This article was originally published in Scrip
A Phase III trial of Clinuvel's lead photoprotective drug Scenesse (afamelanotide) has shown that the drug has the ability to reduce painful phototoxic reactions experienced by patients with a rare genetic disorder called erythropoietic protoporphyria (EPP), according to the Australian-based company.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.